Clinical Trial

Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer .
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2017-06-25; most recent amendment 2025-05-13.
Status change: Not Yet Recruiting → Recruiting 2017-11-15
Trial Details
NCT Number NCT03201861
Lead Sponsor RenJi Hospital
Conditions Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast
Enrollment 762 participants
Start Date 2017-07-27
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-16